Danaher Corporation Buys Aldevron
The medical device giant Danaher Corporation (NYSE: DHR) is back with a new acquisition valued at nearly $10 billion. The company is buying Aldevron for $9.6 billion from private equity firm EQT Partners. Founded in 1998, Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. The business employs 600 people. No other financials for Aldevron were disclosed. The deal was financed by using cash on hand and/or proceeds from the issuance of commercial paper. Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment. The... Read More »
Unchained Labs Sold to The Carlyle Group
Private equity is branching out. Firms are usually swarming the physician group and behavioral health markets, building regional platforms, but we’re now seeing plenty of activity in new sectors, such as healthcare technology and research organizations. With fields such as diagnostics and gene therapy on the rise, it only makes sense for private equity to want a stake in the game. Last week, D.C.-based The Carlyle Group LP (NASDAQ: CG) announced it was buying Unchained Labs from Novo Holdings A/S, Canaan Partners, and TPG Biotech. The deal is valued at $435 million, or 5.80x Unchained Labs’ estimated 2021 revenue. Unchained Labs is a life science tools company focused on solving problems... Read More »
SomaLogic Goes Public With SPAC
They just don’t stop coming. Another private healthcare company has agreed to go public via SPAC in a $1.23 billion deal. SomaLogic is merging with CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company affiliated with Casdin Capital, LLC and Corvex Management LP. SomaLogic is a commercial-stage proteomics company with over 300 established industry partnerships and customers. The company’s pioneering technology platform, SomaScan Assay, measures 7,000 human proteins in a single sample, enabling the possibility of faster, more precise drug discovery for researchers. Artificial intelligence and machine learning-powered bioinformatics algorithms operating in tandem... Read More »
Roche Holding Acquires GenMark Diagnostics
Last week, the pharmaceutical giant Roche Holding AG (SIX: RO) announced a new acquisition for GenMark Diagnostics (NASDAQ: GNMK), a Carlsbad, California lab services company. GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics and reduce the total cost-of-care. GenMark’s eSensor XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic sample-to-answer tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. The deal is valued at $1.8 billion cash, or $24.05 per share, a premium of... Read More »